한국산 담자균류로부터 새로운 항종양 성분을 개발하기 위하여 표고의 일개 균주인 Lentinus edodes DMC7을 인공배지에서 진탕배양하여 그 균사 배양물을 얻었다. 그중 배양 여액으로부터 수용성 고분자 분획을 분리하여 LF-3라고 명명하였다. LF-3는 ICR 마우스에 이식된 Sarcoma 180세포에 대하여 항암작용을 나타내었으며 그 저지율은 53. 1%였다.
To find antitumor constituents in Korean basidiomycetes, the mycelia of Lentinus edodes DMC7, which had shown a good mycelial growth in shakeflasks, were cultured at $27^{circ}C$ on an orbital shaking incubator at 180 rev/min for 12 days. The medium was composed of glucose (50g/l), yeast extract (9g/l), peptone (9g/l), and seven inorganic salts. A water soluble macromolecular fraction, LF-3, was obtained from the culure filtrate by fractionation with ethanol and dialysis using a Visking tube. When LF-3 was administered i.p. at 50mg/kg/day once daily for 10 consecutive days to female ICR mice which were implanted s.c. with sarcoma 180 $(10^6;cells/mouse)$, it exerted a highly significant antitumor activity, with the tumor inhibition ratio of 53. 1%.
